223 related articles for article (PubMed ID: 23810738)
1. Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson's disease.
Prinz A; Selesnew LM; Liss B; Roeper J; Carlsson T
Exp Neurol; 2013 Oct; 248():236-45. PubMed ID: 23810738
[TBL] [Abstract][Full Text] [Related]
2. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
3. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
[TBL] [Abstract][Full Text] [Related]
4. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
[TBL] [Abstract][Full Text] [Related]
5. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
6. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
[TBL] [Abstract][Full Text] [Related]
7. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
Yin LL; Geng XC; Zhu XZ
Brain Res Bull; 2011 Nov; 86(5-6):367-72. PubMed ID: 21963945
[TBL] [Abstract][Full Text] [Related]
8. The acute and long-term L-DOPA effects are independent from changes in the activity of dorsal raphe serotonergic neurons in 6-OHDA lesioned rats.
Miguelez C; Navailles S; De Deurwaerdère P; Ugedo L
Br J Pharmacol; 2016 Jul; 173(13):2135-46. PubMed ID: 26805402
[TBL] [Abstract][Full Text] [Related]
9. What can we expect from the serotonergic side of L-DOPA?
De Deurwaerdère P; Navailles S
Rev Neurol (Paris); 2012 Dec; 168(12):927-38. PubMed ID: 22560009
[TBL] [Abstract][Full Text] [Related]
10. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
[TBL] [Abstract][Full Text] [Related]
11. Changes in the firing activity of serotonergic neurons in the dorsal raphe nucleus in a rat model of Parkinson's disease.
Zhang QJ; Gao R; Liu J; Liu YP; Wang S
Sheng Li Xue Bao; 2007 Apr; 59(2):183-9. PubMed ID: 17437041
[TBL] [Abstract][Full Text] [Related]
12. Serotonergic nerve fibers in L-DOPA-derived dopamine release and dyskinesia.
Nevalainen N; Af Bjerkén S; Gerhardt GA; Strömberg I
Neuroscience; 2014 Feb; 260():73-86. PubMed ID: 24361918
[TBL] [Abstract][Full Text] [Related]
13. Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease.
Chiu WH; Carlsson T; Depboylu C; Höglinger GU; Oertel WH; Ries V
Neuropharmacology; 2014 Apr; 79():212-21. PubMed ID: 24291466
[TBL] [Abstract][Full Text] [Related]
14. Effects of noradrenaline and serotonin depletions on the neuronal activity of globus pallidus and substantia nigra pars reticulata in experimental parkinsonism.
Delaville C; Navailles S; Benazzouz A
Neuroscience; 2012 Jan; 202():424-33. PubMed ID: 22138505
[TBL] [Abstract][Full Text] [Related]
15. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
16. Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia.
García J; Carlsson T; Döbrössy M; Nikkhah G; Winkler C
Neurobiol Dis; 2011 Sep; 43(3):576-87. PubMed ID: 21600983
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
[TBL] [Abstract][Full Text] [Related]
19. Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease.
Mandel RJ
Exp Neurol; 2000 Jan; 161(1):212-9. PubMed ID: 10683287
[TBL] [Abstract][Full Text] [Related]
20. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
